Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) commences trading on the
Australian Securities Exchange (ASX) today following the completion of an initial public offering (IPO) that raised $45m from
The offer was comprised of A$30m of primary capital through the issue of 40 million new shares at $0.75, with the
remaining A$15m forming part of a limited sell down by early investors in the company. The IPO values Aroa at A$225m upon
The IPO received extraordinary support from institutional investors across Australia, New Zealand and other overseas markets,
as well as a strong vote of confidence from existing shareholders who subscribed for approximately half of the funds raised.
Aroa is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. From
more than 10 years of research and development Aroa has developed Endoform®, a proprietary soft tissue regeneration
Endoform® is derived from ovine (sheep) forestomach and includes a basement membrane layer and propria-submucosa
(supportive connective tissue). It acts as a scaffold to grow new tissue lost or damaged through disease or injury, allowing
the patient’s own cells to grow into the matrix to build new tissue and re-establish blood supply. As the patient continues to
heal this is replaced by their own tissue.
The Company lists on the ASX having achieved product revenue of NZ$22.0m in FY2020 (March year-end) and NZ$18.7m in
gross profit. The Company was also EBITDA positive during this period.
Aroa has five commercial products approved for sale in the US based on the Endoform® technology, which have been used in
more than four million procedures targeting chronic wounds, hernia, soft tissue and breast reconstruction. This is in
addition to a new product development pipeline, with all products engineered for the challenges of a specific use case.
Aroa’s products are typically 20%-60% less expensive than competing biological products, while offering superior regenerative
performance, and in many cases are only at a small price premium over synthetic products.
Its success in market comes off the back of validation from peer reviewed publications as well as past and ongoing clinical
studies. Aroa has regulatory clearance in more than 37 countries and a deep patent portfolio.
The total addressable market for its current products exceeds US$1.5 billion2 in the US, with an additional pipeline of new
products to be commercialised with a total addressable market estimated to be more than US$1.0 billion.
The Company plans to grow its sales within its principal market of the United States as well as in other markets such as
Canada, Europe and select Asian countries where it has made early inroads. To date it has achieved sales with more than 600
hospitals in the US as well as being on contract with major group purchasing organisations and surgical distributors.
Aroa employs 140 people across its headquarters in Auckland, its USA operations in San Diego and its USA-based Appulse sales
office, a sales-focused joint venture.
Another key distribution channel for Aroa is via NASDAQ listed partner TELA Bio Inc., a company dedicated to sales and
distribution of Aroa products across its 200 active hospital accounts in the USA. During 2020 TELA Bio expects to expand to 60
employees to cover the top 500 hospitals for soft tissue reconstruction in the USA.
Funds raised in the IPO will be used to invest in sales and marketing, increase manufacturing capacity to meet anticipated
demand and facilitate product development, working capital and repay borrowings.
Bell Potter Securities and Wilsons were Joint Lead Managers to the IPO.
“We’re delighted to reach this key milestone for the business and eagerly welcome our new shareholders to the journey. Since
founding Aroa in 2008 we’ve developed the Endoform® platform technology to deliver clinically effective products and a strong
pipeline which places the business in an ideal position for continued growth across the US and other global markets,” said Aroa
Founder and CEO Brian Ward.
“Our proprietary technology combines advanced regenerative performance with scalable and efficient manufacturing, to target
significant addressable markets with a substantial competitive advantage.
“With our committed board, management and staff, we look forward to continuing to grow the value of Aroa, deliver better
healing outcomes to patients and generate positive returns for our shareholders.”